共 33 条
- [1] RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 183 - 183Porta, C.Procopio, G.Sabbatini, R.Bearz, A.Chiappino, IImarisio, I.Guadalupi, VPaglino, C.Verzoni, E.Ferraris, E.Bajetta, E.
- [2] Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studiesJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Sheng, XinanJin, JieHe, ZhisongHuang, YiranZhou, Ai-PingWang, JinwanRen, Xiu-BaoYe, DingweiZhang, XuQin, ShukuiZhou, Fang-JianGuo, YanfangGuo, Jun
- [3] The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose ReductionJAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 980 - 985Yoo, ChanghoonKim, Jeong EunLee, Jae-LyunAhn, Jin-HeeLee, Dae HoLee, Jung-ShinNa, ShinKim, Choung-SooHong, Jun HyukHong, BumsikSong, CherynAhn, Hanjong
- [4] Dose reductions and delays in patients (pts) with renal cell carcinoma (RCC) treated with sorafenib (SR) or sunitinib (SU): Retrospective analysis of two large US health care claims databasesJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Keefe, S. M.Moyneur, E.Meyers, S.Barghout, V.Flaherty, K. T.
- [5] Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studiesBMC CANCER, 2020, 20 (01)Sheng, XinanJin, JieHe, ZhisongHuang, YiranZhou, AipingWang, JinwanRen, XiubaoYe, DingweiZhang, XuQin, ShukuiZhou, FangjianWang, BinhuiGuo, Jun
- [6] Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studiesBMC Cancer, 20Xinan ShengJie JinZhisong HeYiran HuangAiping ZhouJinwan WangXiubao RenDingwei YeXu ZhangShukui QinFangjian ZhouBinhui WangJun Guo
- [7] Efficacy of two sequential 131I-cG250 treatments at the maximum tolerated dose (MTD) in patients with advanced renal cell carcinoma (RCC).JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 33P - 33PBrouwers, AHOyen, WJVan den Broek, WJBuijs, WCDe Mulder, PHMala, CBoerman, OCBooltink, EOosterwijk, EMulders, PACorstens, FH
- [8] RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF THE TWO MULTI-KINASE INHIBITORS, SORAFENIB AND SUNITINIB, IN PATIENTS (PTS) WITH ADVANCED RENAL CELL CARCINOMA (ARCC)ANNALS OF ONCOLOGY, 2009, 20Porta, CamilloProcopio, GiuseppeCarteni, GiacomoSabbatini, RobertoBearz, AlessandraChiappino, IsabellaRuggeri, Enzo MariaLo Re, GiovanniLandi, LorenzaCalcagno, AnnaImarisio, IlariaPaglino, ChiaraVerzoni, ElenaGuadalupi, ValentinaRizzo, MimmaCanipari, CinziaBajetta, Emilio
- [9] Survival data from patients with advanced or metastatic renal cell carcinoma in routine practice differs significantly from clinical trial data - Analyses from the German clinical RCC RegistryOncology Research and Treatment, 2015, 38 : 204 - 204Marschner, N.Mueller, L.Staehler, M.Nusch, A.Muenz, M.Koska, M.Jaenicke, M.Goebell, P. J.
- [10] Efficacy of avelumab plus axitinib (A plus Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trialANNALS OF ONCOLOGY, 2024, 35 : S1512 - S1513Eto, M.Motzer, R. J.Choueiri, T. K.Haanen, J. B. A. G.Oya, M.Uemura, H.Venugopal, B.Rini, B. I.Miyake, H.Albiges, L.Schmidinger, M.Tomita, Y.Umeyama, Y.Ellers-Lenz, B.Hoffman, J.Larkin, J.